79,841 Shares in Baxter International Inc. (NYSE:BAX) Purchased by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC bought a new stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 79,841 shares of the medical instruments supplier's stock, valued at approximately $2,328,000.

A number of other hedge funds have also modified their holdings of the business. Geode Capital Management LLC boosted its holdings in shares of Baxter International by 1.4% in the 3rd quarter. Geode Capital Management LLC now owns 12,156,660 shares of the medical instruments supplier's stock valued at $460,022,000 after purchasing an additional 170,776 shares during the last quarter. Coho Partners Ltd. acquired a new stake in Baxter International during the third quarter worth about $57,229,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Baxter International by 1.9% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,160,666 shares of the medical instruments supplier's stock worth $33,845,000 after purchasing an additional 21,592 shares during the period. National Pension Service raised its holdings in shares of Baxter International by 22.1% in the 3rd quarter. National Pension Service now owns 1,154,616 shares of the medical instruments supplier's stock worth $43,841,000 after purchasing an additional 208,726 shares during the period. Finally, ARGA Investment Management LP lifted its stake in shares of Baxter International by 148.8% in the 4th quarter. ARGA Investment Management LP now owns 870,601 shares of the medical instruments supplier's stock valued at $25,387,000 after purchasing an additional 520,633 shares in the last quarter. 90.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BAX has been the topic of several research reports. StockNews.com lowered shares of Baxter International from a "buy" rating to a "hold" rating in a report on Monday, November 11th. Citigroup cut their target price on shares of Baxter International from $37.00 to $35.00 and set a "neutral" rating on the stock in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus decreased their price target on shares of Baxter International from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $40.90.

Baxter International Stock Down 1.0 %

Shares of NYSE:BAX traded down $0.31 during trading on Wednesday, hitting $30.29. The company's stock had a trading volume of 2,908,624 shares, compared to its average volume of 4,513,733. The company has a market capitalization of $15.47 billion, a PE ratio of 151.46, a PEG ratio of 9.83 and a beta of 0.61. Baxter International Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $44.01. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. The stock's 50-day moving average price is $30.65 and its two-hundred day moving average price is $34.35.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 2.24%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International's dividend payout ratio (DPR) is currently 340.02%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.